JP5108304B2 - 炎症性腸疾患の治療用製剤及び方法 - Google Patents
炎症性腸疾患の治療用製剤及び方法 Download PDFInfo
- Publication number
- JP5108304B2 JP5108304B2 JP2006525214A JP2006525214A JP5108304B2 JP 5108304 B2 JP5108304 B2 JP 5108304B2 JP 2006525214 A JP2006525214 A JP 2006525214A JP 2006525214 A JP2006525214 A JP 2006525214A JP 5108304 B2 JP5108304 B2 JP 5108304B2
- Authority
- JP
- Japan
- Prior art keywords
- release
- acid
- composition
- drug
- hours
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/606—Salicylic acid; Derivatives thereof having amino groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C245/00—Compounds containing chains of at least two nitrogen atoms with at least one nitrogen-to-nitrogen multiple bond
- C07C245/02—Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides
- C07C245/06—Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides with nitrogen atoms of azo groups bound to carbon atoms of six-membered aromatic rings
- C07C245/08—Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides with nitrogen atoms of azo groups bound to carbon atoms of six-membered aromatic rings with the two nitrogen atoms of azo groups bound to carbon atoms of six-membered aromatic rings, e.g. azobenzene
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Description
実施例3:膜調節錠剤を用いる4−アミノサリチル酸ナトリウムの調節放出製剤
多粒子及び/又は錠剤製剤
Claims (14)
- 4−アミノサリチル酸、5−アミノサリチル酸、それらの製薬的に受容される塩及びエステル、並びにそれらのプロドラッグから選択されるサリチレート及び/又はサリチル酸と、少なくとも1種類の製薬的に受容される賦形剤と、(a)エチルセルロースと組み合わせた、メチルセルロース及びヒドロキシプロピルメチルセルロースの少なくとも1種、または(b)少なくとも2種のアンモニオメタクリレート・コポリマーのいずれかから選択されるポリマー系を含み、調節放出薬剤組成物として製剤化される薬剤組成物であって、周囲pHに依存しない薬剤放出を示す薬剤組成物であって、
該組成物が、試験のために米国薬局方II型装置(パドル)において37℃及び50rpm、pH6.8緩衝剤中で試験した場合に、下記溶解プロフィル:
1時間:10%以下の薬物放出;
2時間:0〜35%薬物放出;
3時間:10〜60%薬物放出;
4時間:20〜60%薬物放出;
6時間:40〜80%薬物放出;及び
12時間:75〜100%薬物放出
を示す、薬剤組成物。 - 該組成物が、試験のために米国薬局方II型装置(パドル)において37℃及び50rpm、pH6.8緩衝剤中で試験した場合に、下記溶解プロフィル:
1時間:5%以下の薬物放出;
2時間:0〜25%薬物放出;
3時間:15〜30%薬物放出;
4時間:40〜50%薬物放出;
6時間:60〜75%薬物放出;及び
12時間:90〜100%薬物放出
を示す、請求項1記載の薬剤組成物。 - 該調節放出組成物が、即時放出コアと半透性膜を含む、請求項1記載の薬剤組成物。
- 該調節放出組成物が、調節放出マトリックス・コアと半透性膜を含む、請求項1記載の薬剤組成物。
- 該サリチレート及び/又はサリチル酸が、4−アミノサリチル酸及び5−アミノサリチル酸、並びにそれらの製薬的に受容される塩若しくはエステルから選択される、請求項1記載の組成物。
- 4−アミノサリチル酸、5−アミノサリチル酸、又はそれらの製薬的に受容される塩若しくはエステルを含む、請求項1記載の組成物。
- 該サリチレート及び/又はサリチル酸が、5,5’−アゾ−ビスサリチル酸、4,5’−アゾ−ビスサリチル酸、4,4’−アゾ−ビスサリチル酸、及びそれらの製薬的に受容される塩から選択される、請求項1記載の組成物。
- 該ポリマー系が、ヒドロキシプロピルメチルセルロースとエチルセルロースとを含む、請求項1記載の組成物。
- 該少なくとも1種類の製薬的に受容される賦形剤が、ヒドロキシプロピルメチルセルロースを含む、請求項8記載の組成物。
- 該ポリマー系が、少なくとも2種のアンモニオメタクリレート・コポリマーを含む、請求項1記載の組成物。
- 該ポリマー系が、機能性被膜及びシーラントを含む、請求項1記載の組成物。
- 機能性被膜がエチルセルロースを含み、シーラントがヒドロキシプロピルメチルセルロースを含む、請求項11記載の組成物。
- 該サリチレート及び/又はサリチル酸が、4,4’−アゾ−ビスサリチル酸である、炎症性腸疾患の治療用の請求項1記載の組成物。
- 該調節放出製剤が、遅延放出性及び持続放出性を有する放出プロフィルを示す、請求項13記載の組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US49936503P | 2003-09-03 | 2003-09-03 | |
US60/499,365 | 2003-09-03 | ||
PCT/IB2004/003059 WO2005021009A2 (en) | 2003-09-03 | 2004-09-02 | Formulations and methods of treating inflammatory bowel disease |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2007504212A JP2007504212A (ja) | 2007-03-01 |
JP2007504212A5 JP2007504212A5 (ja) | 2007-10-18 |
JP5108304B2 true JP5108304B2 (ja) | 2012-12-26 |
Family
ID=34272809
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006525214A Active JP5108304B2 (ja) | 2003-09-03 | 2004-09-02 | 炎症性腸疾患の治療用製剤及び方法 |
Country Status (13)
Country | Link |
---|---|
US (2) | US7737133B2 (ja) |
EP (1) | EP1663253B1 (ja) |
JP (1) | JP5108304B2 (ja) |
AT (1) | ATE489956T1 (ja) |
AU (1) | AU2004267953A1 (ja) |
CA (1) | CA2535923A1 (ja) |
DE (1) | DE602004030353D1 (ja) |
ES (1) | ES2353761T3 (ja) |
IL (1) | IL173684A0 (ja) |
MX (1) | MXPA06002048A (ja) |
NO (1) | NO20061489L (ja) |
WO (1) | WO2005021009A2 (ja) |
ZA (1) | ZA200601356B (ja) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2529984C (en) | 2003-06-26 | 2012-09-25 | Isa Odidi | Oral multi-functional pharmaceutical capsule preparations of proton pump inhibitors |
US7825106B2 (en) * | 2003-09-03 | 2010-11-02 | Agi Therapeutics Ltd. | Modified release formulations and methods of treating inflammatory bowel disease |
US7737133B2 (en) | 2003-09-03 | 2010-06-15 | Agi Therapeutics Ltd. | Formulations and methods of treating inflammatory bowel disease |
AU2005209948B2 (en) | 2004-02-06 | 2009-09-10 | Pharmatel (R&D) Pty Limited | Use of aminosalicylates in diarrhoea-predominent Irritable Bowel Syndrome |
US20080306029A1 (en) * | 2004-05-28 | 2008-12-11 | Salix Pharmaceuticals, Inc. | Prevention, Treatment, and Amelioration of Radiation Induced Enteritis |
US8394409B2 (en) | 2004-07-01 | 2013-03-12 | Intellipharmaceutics Corp. | Controlled extended drug release technology |
US10624858B2 (en) | 2004-08-23 | 2020-04-21 | Intellipharmaceutics Corp | Controlled release composition using transition coating, and method of preparing same |
US20090017110A1 (en) * | 2005-05-31 | 2009-01-15 | Capricorn Pharma Inc. | Modified release formulations of anti-irritability drugs |
US20070015689A1 (en) * | 2005-06-23 | 2007-01-18 | Alza Corporation | Complexation of metal ions with polypeptides |
CN103948609A (zh) * | 2005-08-24 | 2014-07-30 | 萨利克斯药品公司 | 巴柳氮制剂及其生产和应用 |
US7452872B2 (en) | 2005-08-24 | 2008-11-18 | Salix Pharmaceuticals, Inc. | Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives |
US8921344B2 (en) * | 2006-11-03 | 2014-12-30 | Salix Pharmaceuticals, Inc. | Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives |
US8679545B2 (en) * | 2005-11-12 | 2014-03-25 | The Regents Of The University Of California | Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract |
US10064828B1 (en) | 2005-12-23 | 2018-09-04 | Intellipharmaceutics Corp. | Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems |
JP5457830B2 (ja) | 2006-04-03 | 2014-04-02 | オディディ,イサ | オルガノゾル被膜を含む制御放出送達デバイス |
US10960077B2 (en) | 2006-05-12 | 2021-03-30 | Intellipharmaceutics Corp. | Abuse and alcohol resistant drug composition |
WO2008018561A1 (fr) * | 2006-08-11 | 2008-02-14 | Asahi Kasei Chemicals Corporation | Procédé de production de granulé sphérique contenant une substance légèrement hydrosoluble |
US9744137B2 (en) * | 2006-08-31 | 2017-08-29 | Supernus Pharmaceuticals, Inc. | Topiramate compositions and methods of enhancing its bioavailability |
US20090069247A1 (en) * | 2006-10-06 | 2009-03-12 | Blake Paterson | Use of tight junction antagonists to treat inflammatory bowel disease |
ES2555066T3 (es) | 2006-11-17 | 2015-12-28 | Supernus Pharmaceuticals, Inc. | Formulaciones de liberación sostenida de topiramato |
CN102114002B (zh) * | 2006-12-04 | 2016-05-11 | 苏佩努斯制药公司 | 托吡酯的增强的立即释放制剂 |
US20100136125A1 (en) * | 2006-12-28 | 2010-06-03 | Jacobus Pharmaceutical Company, Inc. | Method of treating inflammatory bowel disease |
WO2008115979A2 (en) * | 2007-03-20 | 2008-09-25 | Isp Investments Inc. | Meltable binder for melt granulation and/or pelletization |
US20090036414A1 (en) * | 2007-08-02 | 2009-02-05 | Mutual Pharmaceutical Company, Inc. | Mesalamine Formulations |
WO2009047802A2 (en) * | 2007-10-10 | 2009-04-16 | Lupin Limited | Novel colon targeted modified release bioadhesive formulation of 5-amino salicylic acid or its salts and metabolites thereof |
US20090162434A1 (en) * | 2007-12-21 | 2009-06-25 | Disphar International Bv | Mesalazine tablet |
CA2746767A1 (en) * | 2008-12-17 | 2010-07-08 | Altheus Therapeutics, Inc. | Oral formulations |
CA3014688A1 (en) | 2008-12-19 | 2010-07-15 | Supernus Pharmaceuticals, Inc. | Use of molindone for the treatment of aggression, irritability, or impulsivity |
WO2011123497A1 (en) | 2010-03-31 | 2011-10-06 | Supernus Pharmaceuticals Inc. | Stabilized formulations of cns compounds |
US8597683B2 (en) * | 2010-11-30 | 2013-12-03 | Watson Pharmaceuticals, Inc. | Modified release tranexamic acid formulation |
EP2822542A1 (en) * | 2012-03-07 | 2015-01-14 | Santarus, Inc. | Controlled-release solid dosage forms of mesalamine |
US20140141075A1 (en) | 2012-11-21 | 2014-05-22 | Warner Chilcott Company, Llc | 5-aminosalicylic acid capsule formulation |
JP5897196B1 (ja) * | 2015-10-05 | 2016-03-30 | 大同化成工業株式会社 | 糖又は糖アルコール、膨潤型結合剤、崩壊剤及び高吸収性賦形剤を含む複合化造粒物及びその製造方法 |
US20170119680A1 (en) | 2015-10-30 | 2017-05-04 | R.P. Scherer Technologies, Llc | Extended release film-coated capsules |
AU2019205192A1 (en) * | 2018-01-03 | 2020-07-09 | Ferring B.V. | Oral liquid pharmaceutical compositions of aminosalicylates |
CN112569915B (zh) * | 2020-12-27 | 2023-06-23 | 王晓玉 | 一种煤矿井水除铀吸附剂、及其制备方法和应用 |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS57500432A (ja) * | 1980-03-20 | 1982-03-11 | ||
SE8002322L (sv) * | 1980-03-26 | 1981-09-27 | Pharmacia Ab | Medel for behandling av inflammatoriska tarmsjukdomar |
US4374932A (en) * | 1981-06-08 | 1983-02-22 | G. D. Searle & Co. | 5-ASA Drug delivery system |
ZA825384B (en) * | 1981-07-31 | 1983-05-25 | Tillott J B Ltd | Orally administrable pharmaceutical compositions |
SE8303399D0 (sv) * | 1983-06-15 | 1983-06-15 | Pharmacia Ab | Azo-bis-salicyl syra och salt derav, deras farmaceutiska beredning samt framstellning av syran |
SE8303400D0 (sv) | 1983-06-15 | 1983-06-15 | Pharmacia Ab | Azo-bis-salicylsyra och salt derav samt deras farmaceutiska beredning och anvendning |
US4693895A (en) * | 1984-10-26 | 1987-09-15 | Alza Corporation | Colon delivery system |
US4705515A (en) * | 1984-10-26 | 1987-11-10 | Alza Corporation | Dosage form for administering drug of the colon |
US4627851A (en) * | 1984-10-26 | 1986-12-09 | Alza Corporation | Colonic-therapeutic delivery system |
US4608048A (en) | 1984-12-06 | 1986-08-26 | Alza Corporation | Dispensing device with drug delivery patterns |
US4904474A (en) * | 1988-01-25 | 1990-02-27 | Alza Corporation | Delivery of drug to colon by oral disage form |
US5330998A (en) * | 1988-03-08 | 1994-07-19 | Pfizer Inc. | Thiazolidinedione derivatives as hypoglycemic agents |
US5256675A (en) * | 1989-08-07 | 1993-10-26 | Fujisawa Pharmaceutical Co., Ltd. | Thiazole derivatives, processes for production thereof and pharmaceutical compositions comprising the same |
IE68593B1 (en) * | 1989-12-06 | 1996-06-26 | Sanofi Sa | Heterocyclic substituted acylaminothiazoles their preparation and pharmaceutical compositions containing them |
IT1246382B (it) | 1990-04-17 | 1994-11-18 | Eurand Int | Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon |
IL98087A (en) * | 1990-05-04 | 1996-11-14 | Perio Prod Ltd | Preparation for dispensing drugs in the colon |
SE9002339L (sv) | 1990-07-04 | 1992-01-05 | Kabi Pharmacia Ab | Terapeutisk komposition och foerfarande foer dess framstaellning |
US5519014A (en) | 1990-10-22 | 1996-05-21 | Borody; Thomas J. | Treatment of non-inflammatory and non-infectious bowel disorders |
FR2692484B1 (fr) | 1992-06-22 | 1995-06-30 | Gouchet Franck | Nouvelle forme galenique de 4-asa a liberation controlee. |
WO1995016451A1 (fr) | 1992-06-22 | 1995-06-22 | Franck Arno Gouchet | Comprimes a liberation controlee de 4-asa |
PT621032E (pt) * | 1993-04-23 | 2001-01-31 | Novartis Ag | Dispositivo de distribuicao de libertacao controlada de farmaco |
DK66493D0 (da) * | 1993-06-08 | 1993-06-08 | Ferring A S | Praeparater, isaer til brug ved behandling af inflammatoriske tarmsygdomme eller til at opnaa forbedret saarheling |
JPH072650A (ja) * | 1993-06-18 | 1995-01-06 | Tanabe Seiyaku Co Ltd | 放出部位制御型製剤 |
US5482718A (en) | 1994-03-23 | 1996-01-09 | Hoffmann-La Roche Inc. | Colon-targeted delivery system |
AU689250B2 (en) * | 1994-04-22 | 1998-03-26 | Astellas Pharma Inc. | Colon-specific drug release system |
GB9412394D0 (en) | 1994-06-21 | 1994-08-10 | Danbiosyst Uk | Colonic drug delivery composition |
JPH0840941A (ja) * | 1994-07-29 | 1996-02-13 | Kanegafuchi Chem Ind Co Ltd | 炎症性腸疾患治療製剤 |
US5608048A (en) * | 1995-06-05 | 1997-03-04 | Bristol-Myers Squibb Company | d4 T polymorphic Form 1 process |
US6004581A (en) * | 1995-12-21 | 1999-12-21 | Farmaceutisk Laboratorium Ferring A/S | Modified release oral pharmaceutical composition and method for the treatment of bowel diseases |
US5840332A (en) * | 1996-01-18 | 1998-11-24 | Perio Products Ltd. | Gastrointestinal drug delivery system |
DE19732903A1 (de) * | 1997-07-30 | 1999-02-04 | Falk Pharma Gmbh | Pellet-Formulierung zur Behandlung des Intestinaltraktes |
JP2000103732A (ja) * | 1998-07-28 | 2000-04-11 | Tanabe Seiyaku Co Ltd | 腸内適所放出型製剤 |
WO2000006128A1 (fr) | 1998-07-28 | 2000-02-10 | Tanabe Seiyaku Co., Ltd. | Preparation capable de liberer un medicament au niveau d'un site cible dans l'intestin |
MXPA01003197A (es) | 1998-09-28 | 2004-04-21 | Warner Lambert Co | Suministro enterico y colonico utilizando capsulas de chpm. |
US6733789B1 (en) * | 1999-01-21 | 2004-05-11 | Biovail Laboratories, Inc. | Multiparticulate bisoprolol formulation |
CA2360655C (en) * | 1999-01-29 | 2007-03-20 | Losan Pharma Gmbh | Pharmaceutical compositions |
ITMI991316A1 (it) | 1999-06-14 | 2000-12-14 | Cip Ninety Two 92 S A | Composizioni farmaceutiche orali a rilascio modificato di mesalazina |
DE10013029A1 (de) * | 2000-03-17 | 2001-09-20 | Roehm Gmbh | Mehrschichtige Arzneiform für die Colonfreigabe |
WO2002009769A2 (en) * | 2000-07-27 | 2002-02-07 | Rutgers, The State University Of New Jersey | Therapeutic azo-compounds for drug delivery |
DE50013843D1 (de) | 2000-08-29 | 2007-01-18 | Mepha Ag | Arzneimittel zur behandlung von darmerkrankungen |
CA2359812C (en) | 2000-11-20 | 2004-02-10 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures |
WO2002060415A1 (de) * | 2001-01-31 | 2002-08-08 | Röhm GmbH & Co. KG | Multipartikuläre arzneiform, enthaltend mindestens zwei unterschiedlich überzogene pelletformen |
US7825106B2 (en) * | 2003-09-03 | 2010-11-02 | Agi Therapeutics Ltd. | Modified release formulations and methods of treating inflammatory bowel disease |
US7737133B2 (en) | 2003-09-03 | 2010-06-15 | Agi Therapeutics Ltd. | Formulations and methods of treating inflammatory bowel disease |
-
2004
- 2004-09-01 US US10/930,743 patent/US7737133B2/en active Active
- 2004-09-02 MX MXPA06002048A patent/MXPA06002048A/es not_active Application Discontinuation
- 2004-09-02 CA CA002535923A patent/CA2535923A1/en not_active Abandoned
- 2004-09-02 DE DE602004030353T patent/DE602004030353D1/de active Active
- 2004-09-02 ES ES04769427T patent/ES2353761T3/es active Active
- 2004-09-02 AT AT04769427T patent/ATE489956T1/de not_active IP Right Cessation
- 2004-09-02 EP EP04769427A patent/EP1663253B1/en active Active
- 2004-09-02 JP JP2006525214A patent/JP5108304B2/ja active Active
- 2004-09-02 AU AU2004267953A patent/AU2004267953A1/en not_active Abandoned
- 2004-09-02 WO PCT/IB2004/003059 patent/WO2005021009A2/en active Application Filing
-
2006
- 2006-02-13 IL IL173684A patent/IL173684A0/en unknown
- 2006-02-15 ZA ZA200601356A patent/ZA200601356B/en unknown
- 2006-04-03 NO NO20061489A patent/NO20061489L/no not_active Application Discontinuation
-
2010
- 2010-06-10 US US12/797,655 patent/US7928092B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP1663253A2 (en) | 2006-06-07 |
IL173684A0 (en) | 2006-07-05 |
US20050090473A1 (en) | 2005-04-28 |
EP1663253B1 (en) | 2010-12-01 |
ZA200601356B (en) | 2007-07-25 |
DE602004030353D1 (de) | 2011-01-13 |
US7928092B2 (en) | 2011-04-19 |
CA2535923A1 (en) | 2005-03-10 |
NO20061489L (no) | 2006-05-30 |
MXPA06002048A (es) | 2006-05-25 |
ES2353761T3 (es) | 2011-03-04 |
WO2005021009A2 (en) | 2005-03-10 |
ATE489956T1 (de) | 2010-12-15 |
WO2005021009A3 (en) | 2005-07-14 |
US7737133B2 (en) | 2010-06-15 |
JP2007504212A (ja) | 2007-03-01 |
US20100278917A1 (en) | 2010-11-04 |
AU2004267953A1 (en) | 2005-03-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5108304B2 (ja) | 炎症性腸疾患の治療用製剤及び方法 | |
EP1993517B1 (en) | Modified release formulations and methods of treating inflammatory bowel disease | |
CA2297832C (en) | Pellet-type formulation intended for treating the intestinal tract | |
JP5808670B2 (ja) | 弱塩基性薬物を含む組成物及び徐放性剤形 | |
US6156343A (en) | Controlled release preparation | |
JP2012144577A (ja) | トロスピウムの1日1回剤形 | |
JP2008534681A (ja) | ジピリダモール持続放出製剤及びそれを調製のための方法 | |
JP2009504795A (ja) | 1−(4−クロロアニリノ)−4−(4−ピリジルメチル)フタラジンおよびpH調整剤を含む固体医薬組成物 | |
JP2001517625A (ja) | 活性成分放出制御薬物製剤 | |
WO2006134492A2 (en) | Acarbose methods and formulations for treating chronic constipation | |
US20060280788A1 (en) | Delivery and formulations of mast cell stabilizers | |
US20100080846A1 (en) | Dipyridamole and acetylsalicylic acid formulations and process for preparing same | |
KR20210003323A (ko) | 탐수로신 또는 이의 염산염 함유 제약 조성물 및 이의 제조방법 | |
WO2002066004A1 (fr) | Compositions a liberation controlee de medicament | |
US20090062242A1 (en) | Methods and compositions for treating gastrointestinal conditions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070903 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070903 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110301 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110530 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110606 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110622 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110629 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20110804 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110901 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120213 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120511 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120518 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120813 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120906 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20121005 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5108304 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20151012 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |